PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Prices as of the 2026-10-02 close
Infinitt Healthcare, Korea's leading medical imaging storage and communication system (PACS) provider, improved both revenue and operating profit in 2025, but quarterly net income has been heavily swayed by non-operating items, while repeated minority-shareholder petitions for extraordinary general meetings over the past year have added governance uncertainty.
FY2025 revenue reached KRW 102.39 billion (+6.9% year over year) and operating profit KRW 14.22 billion, lifting the operating margin from 8.1% to 13.9%.
In Q3 2025 the company posted an operating loss of KRW -1.54 billion yet net income to owners of KRW 14.22 billion, illustrating a recurring divergence between operating results and net earnings.
The company holds a 75% share of Korea's tertiary hospital PACS market and 70% of the general hospital market, and supplies products to over 6,300 institutions across 55 countries through eight overseas subsidiaries.
The company has signed imaging-analysis supply agreements with AI diagnostics firms including Lunit, VUNO, and Huron to expand PACS into an AI integration platform, while also holding its own AI solution for colorectal cancer and polyp detection.
Between August and December 2025, minority shareholders filed for court-approved extraordinary general meetings three times—each rejected or withdrawn—reflecting recurring governance friction with controlling shareholder Solborn.
Infinitt Healthcare is a medical IT company centered on PACS (Picture Archiving and Communication System), which stores, transmits, and enables reading of radiological images from X-ray, CT, and MRI equipment.
The company maintains a 75% share of Korea's tertiary hospital PACS market and a 70% share of the general hospital market, giving it a dominant and stable domestic base.
Its product lineup extends beyond radiology PACS into cardiology, radiation oncology (RT PACS), and dental imaging solutions, alongside proprietary high-value-added products such as the "Xelis" package for three-dimensional diagnostic support and "INFINITT DoseM" for radiation dose monitoring.
More recently, the company has expanded into Enterprise Imaging, a platform that integrates imaging data scattered across different hospital departments.
On the AI front, Infinitt holds its own diagnostic solutions while also signing imaging-analysis supply agreements with domestic and overseas AI diagnostics firms including Lunit, VUNO, and Huron, positioning PACS as the essential platform onto which various AI modules can be mounted.
Overseas operations span eight subsidiaries in the United States, Taiwan, Japan, and elsewhere, supplying products to more than 6,300 medical institutions across 55 countries, built on export experience dating back to 2000 and FDA and CE certifications obtained for each new product.
The controlling shareholder is Solborn, a holding-company-type entity, and the business model benefits from recurring maintenance-contract and upgrade demand once PACS systems are installed.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩25.8B | ₩1.3B | 5.1% |
| 2025Q3 | ₩22.1B | -₩1.5B | −7.0% |
| 2025Q4 | ₩30B | ₩11.6B | 38.6% |
| 2026Q1 | ₩32.1B | ₩9.5B | 29.4% |
| 2026Q2 | ₩25.5B | ₩4.9B | 19.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩88.3B | ₩7.7B | ₩100M | 8.7% | 0.1% | 30.2% |
| 2023 | ₩89.4B | ₩3.1B | ₩16.5B | 3.5% | 12.5% | 31.0% |
| 2024 | ₩95.8B | ₩7.7B | ₩37.8B | 8.1% | 22.4% | 29.4% |
| 2025 | ₩102.4B | ₩14.2B | ₩26.4B | 13.9% | 13.8% | 27.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Consolidated revenue for FY2025 came to KRW 102.39 billion, up 6.9% from KRW 95.75 billion in 2024, while operating profit of KRW 14.22 billion was roughly 1.8 times the KRW 7.72 billion recorded in 2024, lifting the operating margin from 8.1% to 13.9%.
Net income attributable to owners, however, fell to KRW 26.4 billion from KRW 37.8 billion in 2024, a decline that appears to reflect a base effect from a larger non-operating gain booked in 2024 relative to operating profit.
Indeed, all four years since 2022 show net income diverging sharply from operating profit: in 2022 operating profit was KRW 7.69 billion but net income was only about KRW 0.13 billion, while in 2023 operating profit of KRW 3.09 billion coincided with net income of KRW 16.46 billion, the opposite pattern.
Looking at recent quarters, Q3 2025 revenue of KRW 22.08 billion came with an operating loss of KRW 1.54 billion, yet net income still reached KRW 14.22 billion, and in Q2 2026 revenue of KRW 25.49 billion and operating profit of KRW 4.93 billion were accompanied by net income of KRW 25.18 billion, more than five times operating profit.
This recurring pattern of large non-operating items means that net income summed over the trailing four quarters (Q3 2025 through Q2 2026) has grown far faster than the pace implied by revenue and operating profit growth.
In contrast, Q1 2026 showed clearer operating-side improvement, with revenue of KRW 32.15 billion and operating profit of KRW 9.47 billion rising together.
Overall, revenue growth and operating margin improvement appear relatively consistent, while net income is subject to considerable year-to-year and quarter-to-quarter volatility driven by items booked outside core operations.
Korea's PACS market is a mature market with already high adoption among tertiary and general hospitals, where Infinitt Healthcare has long held the lead with a 75% share of tertiary hospitals and 70% of general hospitals.
The next growth axis is shifting away from new installations toward upgrade and maintenance demand from existing customers, added value from AI module integration, and overseas market expansion.
In the global medical AI market, Samsung Electronics has expanded its AI investment following its acquisition of ultrasound device maker Medison, and some brokerage research has suggested that Infinitt's historical technical ties to Medison, its former parent, could draw renewed attention.
The competitive landscape features global imaging information system vendors such as GE Healthcare, Philips, and Agfa, alongside domestic AI image-reading specialists like Lunit, VUNO, and JLK that are strengthening their own platforms, resulting in a mix of cooperation and competition.
Infinitt has signed supply agreements with these AI specialists to use PACS as a gateway for AI integration while simultaneously developing its own AI solutions, giving it a position as a partial collaborator rather than a pure competitor.
Government policy directions such as expanded telemedicine and digital healthcare initiatives could increase utilization of medical imaging data, though specific policy timelines and the scope of any benefit remain largely undetermined.
Q1 2026 results showed revenue up 31.1% and operating profit up 232.6% year over year, with net income turning positive, an improvement that industry analysis attributes to growing demand for PACS and medical imaging solutions along with overseas market expansion.
The system's characteristic of generating steady maintenance-contract and upgrade demand after installation continues to support the stability of the revenue base.
Some sources note that FDA approval has laid groundwork for entry into the U.S. market and that AI-based new products could support further global expansion, though specific products and timing require further confirmation.
The company has continued its quarterly cash dividend practice through recent periods as part of its shareholder return policy.
However, how the legal proceedings tied to the repeated minority-shareholder petitions for extraordinary general meetings since the second half of 2025 are ultimately resolved remains a variable that could affect future board composition and decision-making stability.
If overseas revenue expansion and deepening AI partnerships continue, the business portfolio could diversify further, though this remains a directional observation not yet confirmed by specific figures.
Given that recent quarters have repeatedly included sizable non-operating gains within net income, it is worth keeping in mind that earnings-based multiples may appear lower than what core operating performance alone would justify.
The multiple relative to net assets is best considered alongside the steady annual accumulation of equity from retained earnings, and whether any premium exists is a matter of comparison against historical trading ranges.
Shareholder returns have included a history of quarterly cash dividends, though the payout ratio and yield level are worth comparing against sector averages.
Ultimately, valuing this stock requires distinguishing between structural improvement in revenue and operating profit versus the recurring one-off items embedded in net income, and no single metric alone provides a definitive picture.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
A 75% share of tertiary hospitals and 70% of general hospitals supports a stable revenue structure driven by post-installation maintenance and upgrade demand. The improvement in the 2025 operating margin from 8.1% to 13.9% suggests operating leverage is taking hold on this base. The company's long-standing leadership in the domestic market can also function as a barrier to new entrants.
A network supplying more than 6,300 medical institutions across 55 countries through eight overseas subsidiaries provides a growth channel beyond the mature domestic market. Q1 2026 revenue growth of 31.1% and operating profit growth of 232.6% year over year indicate this channel is translating into actual results.
A track record of steadily obtaining FDA and CE certifications also helps accelerate the overseas rollout of new products.
Supply agreements with multiple AI diagnostics firms including Lunit, VUNO, and Huron position PACS as a gateway through which AI modules can be mounted. The company also holds its own AI solution for colorectal cancer and polyp detection, combining external partnerships with in-house technology. If the medical AI market expands, there is potential for increased utilization of the PACS platform itself.
Q3 2025 posted revenue of KRW 22.08 billion with an operating loss of KRW 1.54 billion, before swinging sharply to revenue of KRW 30.0 billion and operating profit of KRW 11.59 billion in Q4.
Such wide quarter-to-quarter swings, likely tied to order recognition timing and cost execution schedules, make it difficult to project a smooth earnings trajectory.
Both Q3 2025 and Q2 2026 saw net income disproportionately larger than operating profit, suggesting non-operating gains and losses accounted for a substantial share of the result. If such items do not recur every quarter, future net income levels could fall short of the trailing four-quarter aggregate.
Between August and December 2025, minority shareholders filed for court-approved extraordinary general meetings three times, with some petitions rejected and others voluntarily withdrawn. If such disputes recur, they could weigh on the predictability of board composition and management decision-making.
The company has stated its intent to resolve sources of governance conflict going forward, but the underlying causes of the disputes have not been publicly resolved.
Conflict between controlling shareholder Solborn and some minority shareholders surfaced through three legal proceedings in the second half of 2025. The possibility that similar agenda items resurface at future general meetings cannot be ruled out, which could affect market assessments of management stability.
The pattern of operating profit and net income diverging sharply by quarter has repeated across multiple years, making it difficult to judge the annual trend from any single quarter's results. The difficulty of anticipating the timing and scale of non-operating items adds uncertainty to earnings estimates.
Global imaging information system vendors and domestic AI image-reading specialists are each strengthening their own platforms, so the possibility that current partnerships shift toward competition in the future cannot be excluded.
The rapid pace of AI technology change also leaves room for existing partnership terms or revenue-sharing structures to change.
It will be worth checking whether Q3 2026 revenue, operating profit, and net income continue recent growth trends and the degree of reliance on non-operating gains.
Whether the quarterly cash dividend policy continues, and whether there is any change in dividend size or frequency, is worth monitoring.
It will be important to check whether issues tied to the repeated 2025 minority-shareholder EGM petitions resurface as agenda items at the annual general meeting, and whether there is any change in the slate of directors or auditors.
It will be worth watching for concrete facts such as new FDA or CE certifications, launches of AI-based new products, or overseas order contracts in markets including the United States.
Infinitt Healthcare has long maintained a dominant share of Korea's PACS market, and in 2025 it showed operating-side improvement with revenue and operating margin advancing together.
However, net income over the trailing four quarters has been heavily influenced by non-operating gains recurring in specific quarters, leaving a structure in which operating results alone cannot fully explain the net income trend.
Overseas revenue expansion, partnerships with AI diagnostics firms, and its own AI solutions stand out as potential growth axes, though much of this remains directional commentary not yet backed by specific figures.
The three repeated minority-shareholder petitions for extraordinary general meetings in the second half of 2025 illustrate that governance-related conflict has not yet been fully resolved, warranting attention to how matters unfold at future general meetings.
On balance, this stock sits at a juncture where a stable market position and operating improvement coexist with net-income volatility and governance uncertainty as offsetting considerations.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.